BELTSVILLE

ION Storage Systems Commissions One of the Country's Largest Solid-State Battery Manufacturing Facilities

Retrieved on: 
Monday, May 6, 2024
SSB, University, DOE, Cell, ION, Safety, Research, Heart, MD, Primary energy, Growth, Cobalt, Money, Saint-Gobain, Inflation, Child, CREB, Temperature, Mining, Architecture, Defense, Nickel, Electric battery

Senator Chris Van Hollen, Congressman Glenn Ivey and others, ION Storage Systems (ION), a Maryland-based manufacturer of safe, high energy density, fast-charging solid-state batteries (SSBs) commissioned one of the largest SSB manufacturing facilities in the United States.

Key Points: 
  • Senator Chris Van Hollen, Congressman Glenn Ivey and others, ION Storage Systems (ION), a Maryland-based manufacturer of safe, high energy density, fast-charging solid-state batteries (SSBs) commissioned one of the largest SSB manufacturing facilities in the United States.
  • Traditional Li-ION batteries simply haven't been up to the task," said Ricky Hanna, CEO of ION Storage Systems.
  • "As we transition to cleaner energy sources and reduce pollution, we need improved battery and energy storage technology.
  • "The commissioning of the state-of-the-art production facility in Beltsville is a great leap forward for ION Storage Systems in safe green battery technology.

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Cancer, Safety, Poster, Colorectal cancer, Research, Insurance, CRC, IND, ASCO, Public expenditure, ADC, Patient, GLP, Society, LCB, Workforce, AACR, Toxicology, Annual general meeting, Ovarian cancer

BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.

Key Points: 
  • BELTSVILLE, Md., May 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today provided a business update and reported its first-quarter 2024 financial results.
  • Included in the ASCO poster presentation will be the additional 20 CRC patients in the 100 mg cohort enrolled in January 2024.
  • Commenced enrolling additional ovarian cancer patients in March 2024 and plan to present data in the second half of 2024.
  • Financial Results for Quarter Ended March 31, 2024
    Cash, cash equivalents, and marketable securities as of March 31, 2024, were $96.0 million as compared to $108.3 million as of December 31, 2023.

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

Retrieved on: 
Wednesday, April 24, 2024
Cancer, MSS, Poster, Colorectal cancer, Johns Hopkins, CRC, MSI-L, ICI, ASCO, Society, Assistant, Annual general meeting, Ovarian cancer

BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.

Key Points: 
  • BELTSVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that clinical trial investigator Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present a poster on clinical data from the Phase 1b portion of a study evaluating NC410 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 – June 4 in Chicago.
  • Title: A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Toxicity, Therapeutic index, KOSDAQ, Partnership, MMAE, Breast, Cancer, Spacecraft, CDX, AACR, PDX, Neoplasm, Pharmacokinetics, LCB, EC50, ADC

The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.

Key Points: 
  • The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
  • The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
  • LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
  • “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

Retrieved on: 
Thursday, April 4, 2024
Biotechnology, AstraZeneca, Merck, Cancer, Doctor of Philosophy, Spacecraft, B7-H4, Antibody, Johnson & Johnson, Immunotoxin, CSO, MedImmune

BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.

Key Points: 
  • BELTSVILLE, Md., April 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific Advisory Board.
  • As an accomplished product developer whose expertise is focused on antibody-drug conjugates (ADCs), Dr. Dixit will support NextCure in its efforts to build and develop its proprietary ADCs, including LNCB74 directed to B7-H4.
  • “We are delighted to have Dr. Dixit join our Scientific Advisory Board, where he will leverage his exceptional experience in developing antibody-drug conjugates,” said Solomon Langermann, PhD, NextCure’s chief scientific officer.
  • “Rakesh is a world authority on ADCs and has an incredible record of researching and developing them.

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Webcast, Conference, Cancer

BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.

Key Points: 
  • BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11th, at 12:45 pm ET.
  • A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com .
  • A replay of the webcast will be available after the event and archived on the website for 30 days.

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

Key Points: 
  • We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
  • Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
  • Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
  • Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

Retrieved on: 
Tuesday, March 5, 2024
Nervous system, Science Advances, Immunotherapy, Spacecraft, Manuscript, ADC, Bi-specific T-cell engager, AGM, Patient, FLRT3, Cancer, Vaccine

The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.

Key Points: 
  • The publication details preclinical data evaluating the role of Fibronectin Leucine-Rich Transmembrane protein-3 (FLRT3) in the inhibition of T cell activity and the use of a monoclonal antibody to reverse these effects.
  • These data demonstrate that cancer cells can exploit AGM protein-protein interactions to evade T cell anti-tumor immunity by acting as checkpoint inhibitors to suppress T cell responses and immune function.
  • Future studies will dissect the roles of membrane and soluble FLRT3 on T cell signaling through UNC5B, and downstream pathways.
  • The data were generated in collaboration with Dr. David Langenau at the Massachusetts General Hospital Research Institute’s Molecular Pathology and Cancer Center.

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Retrieved on: 
Thursday, January 18, 2024
Granulocyte, Neutrophil, Chronic obstructive pulmonary disease, Inflammation, Standard of care, Homeostasis, Ligand, Cancer, Disease, S100, S100 protein, Vaccine

VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.

Key Points: 
  • VSTM-1 is a cell-surface inhibitory receptor highly expressed on granulocytes, including neutrophils, and pulmonary monocytes that functions as a regulator of myeloid cell-driven inflammatory cascades.
  • Inhibitory signaling is induced when VSTM-1 binds to ligands such as cathelicidin and S100 proteins.
  • NextCure developed an agonist monoclonal antibody (mAb) against VSTM-1 to modulate hyperinflammatory conditions, restore homeostasis and prevent disease.
  • The data were presented in a poster presentation at the 2024 Keystone Symposium for Inhibitory Receptors in Immune Homeostasis, Disease and Therapy:

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Retrieved on: 
Thursday, December 21, 2023
Veteran, Osteocalcin, Skeleton, Risk, Osteoporosis, Immobilization, Fracture, Messenger, Tibia, Tetraplegia, BSP, Society, Osteoblast, Cancer, Femur, Blood, S15, Manuscript, Patient, Therapy, Osteoclast, BMD, Medical imaging

The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.

Key Points: 
  • The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
  • Following spinal cord injury, patients typically suffer rapid and extensive bone loss.
  • While anti-resorptive therapies have shown some efficacy in inhibiting bone loss, these agents also inhibit bone formation.
  • Blood and bone structure analyses revealed that the anti-S15 antibody was able to greatly inhibit bone resorption while maintaining bone formation and quality.